NCT00358358View on ClinicalTrials.gov

Chronic Obstructive Pulmonary Disease Endpoints Study

PHASE4CompletedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Fluticasone Propionate/Salmeterol 500/50mcg combination

DRUG

Fluticasone Propionate 500mcg

DRUG

Salmeterol 50mcg

Trial Locations (11)

8201

GSK Investigational Site, Absecon

29303

GSK Investigational Site, Spartanburg

29615

GSK Investigational Site, Greenville

51014

GSK Investigational Site, Tartu

423570

GSK Investigational Site, Nizhnekamsk

2341131

GSK Investigational Site, Valparaíso

7500691

GSK Investigational Site, Santiago

29406-7108

GSK Investigational Site, Charleston

656 045

GSK Investigational Site, Barnaul

105 077

GSK Investigational Site, Moscow

105 229

GSK Investigational Site, Moscow

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00358358 - Chronic Obstructive Pulmonary Disease Endpoints Study | Biotech Hunter | Biotech Hunter